Neonatal sepsis continues to be a major contributor to neonatal morbidity and mortality, especially in preterm and low-birth-weight infants. While traditional clinical signs are often nonspecific, recent studies have highlighted the role of several early biomarkers in risk stratification. The timing of onset (early vs. late) has implications for etiology, with group B Streptococcus and E. coli being predominant in early onset.
Molecular diagnostics and multiplex PCR panels have improved pathogen detection speed. Recent guidelines advocate for precision-based antibiotic initiation to minimize resistance and optimize outcomes. Test your knowledge with this Quick Question on the earliest biomarker in neonatal sepsis. References : International Journal of Contemporary Pediatrics, Frontiers in Pediatrics ##Disclaimer## The content provided on Docplexus is intended for educational purposes…
